NK-ORB Expression of Mu Receptor on Lymphocytes in Rehabilitation

Fibromyalgia Clinical Trial

— NK-ORB  

Official title:

Employment of Natural Killer Opioid Receptor as a Biomarker to Ameliorate the Efficacy of the Rehabilitation Program in a Patient-oriented Strategy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06458569
• Other study ID #: RP 22/30
• Status: Recruiting
• Start date: October 3, 2023
• Est. completion date: April 29, 2026

Study information

• Verified date: April 2024
• Source: IRCCS San Raffaele Roma
• Contact: Lucia Gatta, PhD
• Phone: +390652253440
• Email: lucia.gatta[@]sanraffaele.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic pain is a serious disorder that causes physical suffering and emotional distress. NK cells are cytotoxic granular cells playing a crucial role in innate immunity. Recent studies described modulation of the percentage of B lymphocytes and NK cells expressing the μ opioid receptor as a potential marker for measuring pain. Neuropathic pain sufferers have decreased NK cell function, highlighting the need of further investigating the effect of opioid receptor expression on lympoid cells defining their potential relevance as a pain monitor marker. Opioid receptors expressed on NK, B and T cells are a possible candidate for objective monitoring of pain in patients.

Description:

Pain is a serious global problem Based on the preliminary data, peripheral blood of pain suffering patients who have entered a neurorehabilitation program will be investigated to confirm the modulation of the percentage of Mu-positive NK cells and to evaluate if they could be eligible as predictive markers of chronic pain. All patients in the experimental group will undergo three blood sample collections at specific time points to evaluate the percentage of Mu-positive NK cells, and its modulation according to rehabilitation programs: the day of the enrollment (T0), at half part of the neuro rehabilitation programs (T1) and at the end of neuro-rehabilitation programs (T2). Particularly, the two study groups involved will be in a experimental group (50 consecutive patients who have an NRS >5); a control group (50 patients who have an NRS <5). Peripheral blood will be incubated with different fluorochrome-conjugated antibodies, specific for natural killer cells, in combination with anti-Mu Opioid Receptor (MOR) and the data will be analyze usin flow cytometer and FlowJo. The level of statistical significance will be fixed at p < 0.05. Analyses will be carried out using GraphPad Prism software (v8.00; GraphPad Software). The results are expressed as mean ± SEM The expected results from this study could support the hypothesis that modulation of the µ opioid receptor on NK cells is a valid method for pain measurement, helping to establish an innovative approach in a rehabilitation program.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: April 29, 2026
• Est. primary completion date: July 31, 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

IRCCS San Raffaele Roma patients who entered the neuro-rehabilitation program, aged 18 years older, able to sign a written informed consent.

Exclusion Criteria:

• Patients with oncological or psychiatric diseases.
• Pregnant patients
• Patients with a severe psychiatric disorder (excluding mild depression) or mental/cognitive impairment

Related Conditions & MeSH terms

• Fibromyalgia

Intervention

Other:
• Rehabilitation
3-weeks rehabilitation in hospital

Locations

Country	Name	City	State
Italy	IRCCS San Raffaele	Roma

Sponsors (1)

Lead Sponsor	Collaborator
IRCCS San Raffaele Roma

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of percentage of Mu-positive NK cells as predictive markers of pain in suffering patients	Peripheral blood of pain suffering patients who have entered a neurorehabilitation program will be investigated to confirm the modulation of the percentage of Mu-positive NK cells and to evaluate if they could be eligible as predictive markers of chronic pain by correlating it to the level of pain calculated with Numeric Pain Rating Scale.	3 weeks